SCHEMBL139849

SCHEMBL139849

CC(C)(C)N(C=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTT P42858 2/20 0.39
ALDH1A1 P00352 4/20 0.36
NPSR1 Q6W5P4 2/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
POLB P06746 2/20 0.35
NPC1 O15118 1/20 0.35
ESR1 P03372 1/20 0.35
CYP2A6 P11509 1/20 0.35
GLA P06280 1/20 0.34
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28295661 0.79 KMT2A (0.39) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL23896443 0.77 MEN1 (0.37) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL27764787 0.76 ALDH1A1 (0.36) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL2968738 0.76 ALDH1A1 (0.36) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL27972619 0.76 KCNA5 (0.41) CYP3A4HTTALDH1A1CYP2A6
SCHEMBL22200237 0.74
SCHEMBL16863748 0.73 MAPT (0.42) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL14065799 0.70 ALDH1A1 (0.39) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL140771 0.70 MEN1 (0.33) MEN1KMT2ACYP3A4CYP2C9CYP2C19
SCHEMBL66606 0.70 MEN1 (0.48) MEN1KMT2ASMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110914234-B Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine 广东东阳光药业有限公司 2023-06-23 CN disclosed
CN-110914234-A Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine 广东东阳光药业有限公司 2020-03-24 CN disclosed
CN-103301953-A 6-aryl amido hexyl hydroximic acid collecting agent and preparation and application methods thereof UNIV CENTRAL SOUTH 2013-09-18 CN disclosed
US-8530687-B2 Catalysts, methods of making catalysts, and methods of use UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2013-09-10 US disclosed
US-8530687-B2 Catalysts, methods of making catalysts, and methods of use UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2013-09-10 US disclosed
US-8530687-B2 Catalysts, methods of making catalysts, and methods of use UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2013-09-10 US disclosed
US-20120059182-A1 Catalysts, Methods of Makting Catalysts, and Methods of Use UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-03-08 US disclosed
US-20120059182-A1 Catalysts, Methods of Makting Catalysts, and Methods of Use UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-03-08 US disclosed
US-20120059182-A1 Catalysts, Methods of Makting Catalysts, and Methods of Use UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2012-03-08 US disclosed
US-4157333-A CONDENSATION OF 1,2-METHYLENEDIOXYBENZENE WITH N-ALKYLOORMANILIDE, HYDROLYSIS MITSUI TOATSU CHEMICALS, INC. (JP) 1979-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059182-A1 Catalysts, Methods of Makting Catalysts, and Methods of Use DKC1, ADCK1, AMD1 MEN1 919/4885KMT2A 410/4885CYP3A4 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.